BioXcel Therapeutics, Inc.
Every calculator, already run for BTAI
Open the full toolkit →You have the numbers on BTAI. Get the argument.
A written report on which of these readings actually decide the outcome for BioXcel Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering BTAIOwnership & short interest
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid…
BTAI — frequently asked
Is BTAI a buy right now?
Wall Street's consensus rating on BioXcel Therapeutics, Inc. is none across 4 analysts, with a mean price target of $14.00 (+1510% vs. the current $0.87). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare BioXcel Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For BioXcel Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BTAI research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on BioXcel Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.